| 1 |
Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers
Deepak L. Bhatt, Charles V. Pollack, Jeffrey Ian Weitz et al. · New England Journal of Medicine
Open access |
17 Mar 2019 |
137 |
| 2 |
One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer
Kelli M. Luginbuhl, Jeffrey L. Schaal, Bret R. Umstead et al. · Nature Biomedical Engineering
Open access |
5 Jun 2017 |
129 |
| 3 |
Aldosterone and aldosterone synthase inhibitors in cardiorenal disease
Subodh Verma, Avinash Pandey, Arjun K. Pandey et al. · American Journal of Physiology-Heart and Circulatory Physiology
|
22 Dec 2023 |
60 |
| 4 |
Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery
Deepak L. Bhatt, Charles V. Pollack, C. David Mazer et al. · NEJM Evidence
|
22 Dec 2021 |
58 |
| 5 |
The design and synthesis of novel, phosphonate-containing transient receptor potential melastatin 8 (TRPM8) antagonists
Jay M. Matthews, Na Qin, Raymond W. Colburn et al. · Bioorganic & Medicinal Chemistry Letters
Open access |
27 Feb 2012 |
37 |
| 6 |
Population pharmacokinetic–pharmacodynamic modeling of PB2452, a monoclonal antibody fragment being developed as a ticagrelor reversal agent, in healthy volunteers
Steven J. Kathman, Jeffery J. Wheeler, Deepak L. Bhatt et al. · CPT Pharmacometrics & Systems Pharmacology
Open access |
29 Oct 2021 |
11 |
| 7 |
VASOMERA™, A NOVEL VPAC2-SELECTIVE VASOACTIVE INTESTINAL PEPTIDE AGONIST, ENHANCES CONTRACTILITY AND DECREASES MYOCARDIAL DEMAND IN DOGS WITH BOTH NORMAL HEARTS AND WITH PACING-INDUCED DILATED CARDIOMYOPATHY
Carlos L. del Rio, Robert J. D. George, Pamela Kloepfer et al. · Journal of the American College of Cardiology
Open access |
Mar 2013 |
9 |
| 8 |
A safety and pharmacodynamic study of the highly selective aldosterone synthase inhibitor PB6440 in the cynomolgus monkey
Bertram Pitt, Deepak L. Bhatt, Robert J. Schotzinger et al. · European Heart Journal
Open access |
Oct 2022 |
3 |
| 9 |
Evaluation of Vasomera™, a Novel VPAC2-Selective Vasoactive Intestinal Peptide Agonist, in Rats With Doxorubicin-Induced Cardiomyopathy: Evidence for Chronic Cardio-Protection.
Bradley L. Youngblood, Steven Yeh, Lynne Georgopoulos et al. · Journal of Cardiac Failure
|
Aug 2012 |
3 |
| 10 |
Bentracimab demonstrates reversal of antiplatelet effects of ticagrelor: impact of hematocrit and generic versions of ticagrelor in vitro
B Curry, R Brown, Deepak L. Bhatt et al. · European Heart Journal
Open access |
Oct 2022 |
2 |
| 11 |
2350Evaluation of the pharmacodynamics of a ticagrelor reversal agent PB2452
Lisa K. Jennings, Benjamin J. Curry, Deepak L. Bhatt et al. · European Heart Journal
|
Oct 2019 |
2 |
| 12 |
Vasomera™, a Novel VPAC2-Selective Vasoactive Intestinal Peptide Agonist, Improves Ventriculo-Arterial Coupling and Decreases Myocardial Demand in Sheep with Induced Ischemic Heart Failure
Carlos L del Rio, Bradley L. Youngblood, Robert S. George et al. · Journal of Cardiac Failure
Open access |
Aug 2014 |
1 |
| 13 |
ENHANCED INHIBITION OF ALDOSTERONE PRODUCTION BY PB6440, A NOVEL AND VERY HIGHLY SELECTIVE ALDOSTERONE SYNTHASE INHIBITOR
James Jowett, Bertram Pitt, Robert J. Schotzinger et al. · Journal of the American College of Cardiology
Open access |
Mar 2023 |
0 |
| 14 |
BLEEDING AND PROCEDURE RATES AMONG PATIENTS TREATED WITH P2Y12 INHIBITORS COMPARED WITH FACTOR XA INHIBITORS: A REAL-WORLD ANALYSIS
Amanda M. Kong, John Lee, Kristin A. Evans et al. · Journal of the American College of Cardiology
Open access |
May 2021 |
0 |
| 15 |
Acute pulmonary artery hypertension in closed-chest anesthetized rats and the sustained pulmonary artery vaso-relaxation following treatment with a novel vasoactive intestinal peptide
Brad L. Youngblood, Carlos L del Rio, Steven Yeh et al. · Journal of Pharmacological and Toxicological Methods
|
Jul 2013 |
0 |